Clinical Trials Browser

Phase 3 × Carcinoma, Non-Small-Cell Lung × alectinib × Clear all

NCT06765109 2026-06-02

ALKAZAR

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT02075840 2026-05-29

ALEX

Phase 3 Completed

303 enrolled 32 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3 Active not recruiting

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT05170204 2026-05-06

HORIZON 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02604342 2019-10-29

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Phase 3 Completed

119 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung